Changchun High-Tech Industry (000661.SZ): GenSci 141 Ointment by Gold Sai Pharmaceutical Company has received approval for clinical trial registration.

16:04 26/12/2025

Changchun High-Tech (000661.SZ) announced that its subsidiary, Changchun Goldstar Pharmaceutical Co., Ltd. (referred to as "Goldstar Pharmaceutical"), recently received an "Acceptance Notice" issued by the National Medical Products Administration for the registration clinical trial application of GenSci141 ointment.

Changchun High-Tech Industry (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinsai Pharmaceutical"), has received a "Notice of Acceptance" issued by the National Medical Products Administration for the clinical trial application of GenSci141 ointment. It is reported that GenSci141 ointment is a dihydrotestosterone ointment developed by Jinsai Pharmaceutical, which mainly acts on target tissues through paracrine secretion, and belongs to chemical drugs categories 2.2 and 2.4.

Zhejiang Huahai Pharmaceutical's subsidiary HB0025 injection has started Phase III clinical trials.

Zhejiang Huahai Pharmaceutical (600521.SH) has obtained the drug registration certificate for Naloxone Hydrochloride Injection.

Shandong Lukang Pharmaceutical (600789.SH) subsidiary obtained registration certificate for finasteride tablets.

Zhejiang Huahai Pharmaceutical's subsidiary HB0025 injection has started Phase III clinical trials.

Zhejiang Huahai Pharmaceutical (600521.SH) has obtained the drug registration certificate for Naloxone Hydrochloride Injection.

Shandong Lukang Pharmaceutical (600789.SH) subsidiary obtained registration certificate for finasteride tablets.